The primary objective of this study is to determine if left atrial appendage closure (LAAC)
with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants
in patients with non-valvular atrial fibrillation.
This study is a prospective, randomized, multi-center global investigation. Subjects will be
randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group")
or a commercially available non-vitamin K oral anticoagulant ("Control Group").
Atrial Fibrillation, Stroke, Bleeding
WATCHMAN FLX LAAC Device,
Non-Vitamin K Oral Anticoagulant
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.